Healthcare IT Vet Takes Reins at Accelrys; Declares Discipline Key to Growth | GenomeWeb

Mark Emkjer wants to put Accelrys through boot camp. “I think we need more discipline. I think we absolutely need to obsess about our clients,” he told BioInform last week, just 72 hours into his new position as president of the Pharmacopeia subsidiary. Emkjer, who replaces former Accelrys COO Mike Stapleton, said he thinks this client-centered strategy will bring the company to its eventual goal of $200 million in revenues.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.